Establishes the rare disease advisory council to identify best practices, raise awareness regarding rare diseases, evaluate barriers to access to care, and to make recommendations to the legislature and the governor.
A01296 would create a Rare Disease Advisory Council within the New York State Department of Health. The council’s purpose is to identify best practices, raise awareness of rare diseases, evaluate barriers to care, and make recommendations to the governor and Legislature. The bill defines a rare disease as one affecting fewer than 200,000 people in the United States and allows an existing or previously convened body to be repurposed to satisfy the new council requirement.
The council would include state officials and appointees from the executive and legislative branches, along with members representing clinicians, researchers, insurers, the biopharma industry, patients, caregivers, and patient organizations. It would meet at least quarterly, hold public meetings, maintain a public website, and issue annual reports with findings, recommendations, and a list of publicly accessible resources on diagnosis, treatment, coverage, and education. The council would also be tasked with reviewing barriers to access, emergency planning for continuity of care, and advising on Medicaid drug utilization review matters related to rare and orphan diseases and certain emerging therapies, though it would have no authority over Medicaid decisions.
The bill’s main legal effect would be to add a new section to the Public Health Law establishing a permanent advisory structure focused on rare disease policy. It would not create direct benefits or mandates for patients or providers, but it would require the Department of Health to support the council, post reports and recommendations, and incorporate recommendations into future state health planning where appropriate. It also authorizes the council to identify and use public or private funding sources for implementation.
The overall sentiment reflected in the committee votes is strongly favorable. The bill advanced unanimously in the Assembly Health Committee and Assembly Rules Committee, and with only two nays in Ways and Means, suggesting broad bipartisan support and little opposition at the committee level. The absence of recorded transcript debate also suggests the measure was not especially controversial in committee.
Any potential points of contention appear limited and practical rather than ideological. The bill’s inclusion of representatives from insurers and the biopharma industry alongside patients and caregivers could raise questions about balance and influence, but the text explicitly says patient and caregiver voices should be prioritized. Another possible issue is that the council is advisory only and cannot direct Medicaid policy, which may limit expectations among advocates seeking more immediate action on access, coverage, or treatment costs.
The bill would amend the New York Public Health Law by adding a new section establishing a Rare Disease Advisory Council within the Department of Health. It would create a formal state advisory body with specified membership, meeting, reporting, public notice, and website requirements, and it would direct the council to study rare disease access, emergency planning, treatment barriers, and policy recommendations. The bill would also require the Department of Health to receive and post the council’s reports and recommendations and consider them in future health planning, while making clear that the council has no authority over Medicaid decisions.
Committee action indicates generally strong support for the bill. It passed the Assembly Health Committee unanimously, moved through Ways and Means with only two negative votes, and then passed the Assembly Rules Committee unanimously. With no committee transcript available, there is no recorded substantive debate, but the voting pattern suggests the measure is viewed as a low-conflict public health initiative with broad appeal among lawmakers.
The main areas that could draw scrutiny are the council’s composition and its limited authority. Because the council includes insurers and biopharma representatives as well as patients and caregivers, some advocates may be concerned about industry influence, although the bill attempts to prioritize patient and caregiver voices. Another possible point of contention is that the council is advisory only and cannot compel Medicaid action, which may disappoint stakeholders hoping for stronger coverage or reimbursement reforms. Otherwise, the bill appears relatively noncontroversial based on the committee votes.